ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 226 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q1 2023. The put-call ratio across all filers is 1.03 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $112,661 | -32.4% | 3,160,160 | -12.6% | 0.02% | -26.1% |
Q2 2023 | $166,761 | +17.3% | 3,614,992 | +2.0% | 0.02% | +9.5% |
Q1 2023 | $142,106 | -25.1% | 3,543,761 | -13.5% | 0.02% | -32.3% |
Q4 2022 | $189,785 | -99.9% | 4,096,388 | -13.9% | 0.03% | -3.1% |
Q3 2022 | $196,987,000 | -69.4% | 4,756,956 | -55.9% | 0.03% | -60.5% |
Q2 2022 | $643,144,000 | -25.5% | 10,780,156 | -9.3% | 0.08% | -6.9% |
Q1 2022 | $863,073,000 | -10.9% | 11,884,786 | +3.1% | 0.09% | 0.0% |
Q4 2021 | $969,145,000 | -6.2% | 11,525,089 | +0.6% | 0.09% | -10.3% |
Q3 2021 | $1,033,491,000 | -1.5% | 11,459,046 | +4.2% | 0.10% | 0.0% |
Q2 2021 | $1,048,775,000 | -13.7% | 10,999,214 | +3.1% | 0.10% | -20.5% |
Q1 2021 | $1,215,090,000 | -7.3% | 10,671,786 | +12.7% | 0.12% | -9.6% |
Q4 2020 | $1,311,000,000 | +91.1% | 9,470,492 | +13.4% | 0.14% | +70.9% |
Q3 2020 | $686,182,000 | +14.4% | 8,348,729 | +8.9% | 0.08% | +5.3% |
Q2 2020 | $599,683,000 | +186.6% | 7,666,617 | +62.8% | 0.08% | +127.3% |
Q1 2020 | $209,213,000 | +9.1% | 4,708,822 | +4.8% | 0.03% | +32.0% |
Q4 2019 | $191,843,000 | +0.6% | 4,491,769 | +0.8% | 0.02% | -7.4% |
Q3 2019 | $190,610,000 | -34.9% | 4,455,585 | -3.4% | 0.03% | -34.1% |
Q2 2019 | $292,858,000 | +20.6% | 4,611,939 | +31.7% | 0.04% | +13.9% |
Q1 2019 | $242,873,000 | +104.6% | 3,501,623 | +28.2% | 0.04% | +80.0% |
Q4 2018 | $118,717,000 | -44.0% | 2,730,381 | -1.7% | 0.02% | -35.5% |
Q3 2018 | $212,075,000 | -1.3% | 2,778,029 | -0.7% | 0.03% | -6.1% |
Q2 2018 | $214,959,000 | +87.2% | 2,796,392 | +24.2% | 0.03% | +83.3% |
Q1 2018 | $114,814,000 | +16.7% | 2,251,701 | +6.2% | 0.02% | +12.5% |
Q4 2017 | $98,365,000 | +13.7% | 2,120,855 | +30.5% | 0.02% | +6.7% |
Q3 2017 | $86,533,000 | -20.9% | 1,624,720 | -7.8% | 0.02% | -25.0% |
Q2 2017 | $109,412,000 | -3.4% | 1,761,589 | +5.4% | 0.02% | -4.8% |
Q1 2017 | $113,248,000 | -3.5% | 1,670,824 | +0.1% | 0.02% | -8.7% |
Q4 2016 | $117,383,000 | -9.5% | 1,669,507 | -8.7% | 0.02% | -11.5% |
Q3 2016 | $129,650,000 | +66.5% | 1,827,607 | +14.8% | 0.03% | +62.5% |
Q2 2016 | $77,864,000 | -8.9% | 1,591,977 | +18.0% | 0.02% | -11.1% |
Q1 2016 | $85,446,000 | -43.6% | 1,349,637 | -0.1% | 0.02% | -43.8% |
Q4 2015 | $151,599,000 | +15.8% | 1,351,387 | -0.6% | 0.03% | +10.3% |
Q3 2015 | $130,881,000 | +8.4% | 1,358,955 | +15.2% | 0.03% | +16.0% |
Q2 2015 | $120,732,000 | +56.1% | 1,179,140 | -5.4% | 0.02% | +56.2% |
Q1 2015 | $77,354,000 | +33.9% | 1,245,840 | -5.3% | 0.02% | +33.3% |
Q4 2014 | $57,752,000 | -22.5% | 1,316,140 | -0.1% | 0.01% | -25.0% |
Q3 2014 | $74,536,000 | +38.9% | 1,316,890 | +5.1% | 0.02% | +33.3% |
Q2 2014 | $53,674,000 | -17.7% | 1,253,279 | -9.9% | 0.01% | -20.0% |
Q1 2014 | $65,189,000 | – | 1,390,979 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
GREAT POINT PARTNERS LLC | 727,426 | $25,932,737 | 4.72% |
RTW INVESTMENTS, LP | 5,405,089 | $192,691,423 | 4.07% |
First Light Asset Management, LLC | 1,125,032 | $40,107,391 | 3.81% |
CHI Advisors LLC | 215,000 | $7,664,750 | 3.04% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 250,052 | $8,914,354 | 3.00% |
SPHERA FUNDS MANAGEMENT LTD. | 259,135 | $9,238,163 | 1.68% |
Rock Springs Capital Management LP | 1,476,441 | $52,635,122 | 1.41% |
SUVRETTA CAPITAL MANAGEMENT, LLC | 679,459 | $24,222,713 | 1.31% |
Privium Fund Management B.V. | 115,241 | $4,108,341 | 1.22% |
SECTOR GAMMA AS | 115,166 | $4,105,668 | 1.05% |